Riluzole in the control of obsession in bipolar patients

Comparison of the effect of bipolar disorder treatment (Lithium+Olanzapin+Clonazepam) and placebo with Riluzole-containing regimen in controlling obsessive symptoms of bipolar patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211118053093N4

Enrollment

Registered

2022-08-19

Start date

2022-08-22

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BMD. Bipolar disorder

Interventions

Intervention 1: Intervention group: It includes 20 patients who receive riluzole in addition to the main drugs, and in weeks 0, 4, 8, 12, and 16, they must complete the Yale Brown Obsessive Compulsive

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Having DSM 5 criteria for bipolar disorder Having a score higher than 18 in the Y_BOCS test

Exclusion criteria

Exclusion criteria: Pregnancy Addiction Medical problems

Design outcomes

Primary

Measure	Time frame
Yale Brown Obsessive-Compulsive Scale score. Timepoint: week 0and4and8and12and16. Method of measurement: Yale Brown Obsessive-Compulsive Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Razeghian Jahromi

Shiraz University of Medical Sciences

leilarazeghian1366@gmail.com+98 71 3260 5701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026